Inhaler market was valued at $36.2 billion in 2024 and is projected to reach $71.4 billion by 2035, growing at a CAGR of 5.9% during the forecast period (2025–2035). The shift to eco-friendly inhalers is being pushed by increased environmental concerns and regulatory pressure to minimize the use of high global warming potential (GWP) propellants usually found in standard metered-dose inhalers (MDIs). These inhalers considerably increase healthcare-related carbon emissions. In response, Kindeva, AstraZeneca, and GSK are developing inhalers using low-GWP or propellant-free technologies.
Browse the full report description of “Inhaler Market Size, Share & Trends Analysis Report by Type (Metered-dose, Dry powder, and Soft mist inhalers), by Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, and Others), and by Distribution Channel (Online and Offline), Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/inhaler-market
In October 2023, the EU obtained a provisional agreement to gradually phase out all F-gases by 2050. EU F-gas legislation aims to reduce the use of high-GWP propellants in pressurized metered-dose inhalers (pMDIs) as it contributes to climate change. Under this regulation, inhaler manufacturers are encouraged to switch to low-GWP propellants (like HFO-1234ze). This supports the EU’s climate goals by reducing greenhouse gas emissions from medical products.
For instance, in May 2024, Kindeva Drug Delivery, a global leader in drug-device combination products, announced its investment in a second manufacturing line at its Loughborough, UK facility. This new line will support the production of pressurized metered-dose inhalers (pMDIs) formulated with low global warming potential (GWP) propellants, reinforcing the company’s commitment to sustainable pharmaceutical solutions. This new line will be capable of handling both HFA-152a and HFO-1234ze propellants that have a GWP of 90% and 99.9% lower than the industry standard HFA-134a, respectively, and is anticipated to be operational in 2026.
Market Coverage
• The market number available for – 2024-2035
• Base year- 2024
• Forecast period- 2025-2035
• Segment Covered-
o By Type
o By Disease Indication
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape - GlaxoSmithKline PLC, Cipla Ltd., Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., among others.
Key questions addressed by the report.
Global Inhaler Market Report Segment
By Type
By Disease Indication
By Distribution Channel
Global Inhaler Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/inhaler-market